The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 

 

This Article
-Abstract
-Full Text
NEJM -- Talpaz M et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. 2006;354(24):2531-41 -- Supplementary Animation

Supplement to: Talpaz M et al. Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias. N Engl J Med 2006;354(24):2531-41.




View Animation
(663 KB)
Activity of the ABL kinase inhibitor dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias

The three-dimensional structure of ABL kinase (green) bound to dasatinib (on left) and imatinib (on right). Dasatinib and imatinib are rendered in stick (carbon atoms in aqua and magenta, respectively). The P loop of ABL is colored yellow, and the activation loop is colored red. Note the diverging direction of the activation loop in the two structures. Imatinib would not be able to bind to the active conformation of ABL because of a clash with the activation loop when it is positioned in the dasatinib-bound ABL conformation. Dasatinib, on the other hand, would be able to bind to the activation loop in either conformation.
 

This animation is in Flash format. If you do not have Flash, go to www.macromedia.com to download their free player. If you still cannot view the animation or have other questions, email us at webmaster{at}nejm.org.


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.